

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

215239Orig1s000

OFFICER/EMPLOYEE LIST

MEMORANDUM: Department of Health and Human Services Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research

DATE: October 26, 2023

TO: Administrative file for NDA 215239 (FRM-ADMIN-01)

FROM: Brenda Reggett, Senior Regulatory Health Project Manager, DN1
DRO-N/ORO/OND/CDER

SUBJECT: **Officer/Employee List**
Application/Drug: **NDA 215239 Agamree (vamorolone) oral suspension**

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Abellard, Cassandra
AbuAsal, Bilal
Alfaro, Cara
Bhattaram, Atul
Buracchio, Teresa
Carbone, David
DeGraw, Stephanie
Falade, Leah
Freed, Lois
Freilich, Emily
Heimann, Martha
Kehoe, Theresa
Khan, Khalid
Kitabi, Eliford
Marcsisin-Rogers, Renee
Mehta, Mehul
Moukhtara, Aline
Nookala, Anantha Ram
Nguyen, Maria
Paine, Rainer
Peters, Tracy
Ponta, Andrei
Reggett, Brenda
Sharma, Vishnu
Toscano, Christopher
Williams, Marcia
Wu, Ta-Chen
Zhu, Hao

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BRENDA L REGGETTZ
10/26/2023 02:31:50 PM